Financial Daily from THE HINDU group of publications
Wednesday, Apr 07, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Announcements
Marketing - Standards & Benchmarks
Industry & Economy - Health


Nicholas Piramal backs cough syrup quality

Our Bureau

Mumbai , April 6

NICHOLAS Piramal India Ltd (NPIL) on Monday said it stood by the quality of its paediatric cough syrup, Tixylix.

The company statement comes following recent media reports that the Delhi government's Drug Control Department had said the product was sub-standard. Further, the company added that it would contest the testing procedure adopted by the Ghaziabad-based laboratory of the Delhi Drug Control Department (DCD).

NPIL officials told Business Line that the developments had happened 18 months ago, when the DCD's officials had tested products with one of NPIL's distributors.

"The procedure used to test our product at the Ghaziabad laboratory is inappropriate. One requires sophisticated machinery to test the Codine element. Besides, we have not been show-caused till now by the Department," the NPIL official said.

Significantly, the company points out: "Tixylix contains a controlled substance and is subject to strict testing by the drug administration in Gujarat, where it is manufactured. The Baroda laboratory of Gujarat FDA has tested the samples of the same product and reported it to be of `Standard Quality.'"

More Stories on : Announcements | Standards & Benchmarks | Health | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Zuari Ind gets Rs 66-cr I-T notice


IOC in talks with 3 nations for retailing
Nicholas Piramal backs cough syrup quality
Lupin to launch more branded drugs in US — Rolls out anti-infective SupraxO
Ranbaxy plans to widen AIDS drugs' reach
Disclosure document mandatory for ESOP optees, says SEBI
India Inc wants expert panel to be formed to review laws
Award for Orchid Chemicals
IOC mulls FCCB issue
2 OCBs get Govt nod to buy equity shares of Orchid
Ucal to hold talks with Escorts Auto on stake buy
Faber to hike stake in Indian joint venture
Ranbaxy to set up arm in Australia; enter NZ also
Ponni Sugars (Erode) to set up distillery — Plans Rs 12-cr investment
Tata Tele to support Childline
BHEL-Ramachandrapuram turnover up 27 pc
BHEL Bangalore units post 22% sales growth
Pitti Laminations' net worth turns positive



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line